AstraZeneca PLC (AZN)

AZN Income Statement

Revenue, expenses, and profitability analysis

AZN Quarterly Income Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/30/2025	12/31/2024	09/30/2024	06/30/2024
Gross Profit	49.369B	12.610B	12.385B	12.390B	11.984B	11.347B	12.166B	10.484B	10.755B
Revenue	60.439B	15.288B	15.503B	15.191B	14.457B	13.588B	14.891B	13.565B	12.938B
Cost of Goods Sold	11.070B	2.678B	3.118B	2.801B	2.473B	2.241B	2.725B	3.081B	2.183B
Gross Profit Margin	82.5%	82.5%	79.9%	81.6%	82.9%	83.5%	81.7%	77.3%	83.1%
Total Operating Expenses	35.054B	8.364B	9.407B	8.807B	8.476B	7.673B	10.130B	8.378B	8.009B
Research & Development	14.565B	3.492B	3.862B	3.663B	3.548B	3.159B	4.677B	3.115B	3.008B
Selling, General & Administrative	20.946B	5.061B	5.645B	5.233B	5.007B	4.627B	5.553B	5.288B	5.061B
Operating Income (EBIT)	14.315B	4.246B	2.978B	3.583B	3.508B	3.674B	2.036B	2.106B	2.746B
Operating Margin	27.8%	27.8%	19.2%	23.6%	24.3%	27.0%	13.7%	15.5%	21.2%
Income Before Tax (EBT)	12.914B	3.914B	2.629B	3.244B	3.127B	3.402B	1.666B	1.828B	2.397B
Interest Income	349.000M	73.000M	123.000M	85.000M	68.000M	84.000M	64.000M	183.000M	100.000M
Interest Expense	1.738B	393.000M	472.000M	434.000M	439.000M	349.000M	429.000M	457.000M	443.000M
Other Income/Expense	-1.401B	-332.000M	-349.000M	-339.000M	-381.000M	-272.000M	-370.000M	-278.000M	-349.000M
Net Income	10.389B	3.080B	2.326B	2.533B	2.450B	2.916B	1.500B	1.429B	1.927B
Income Tax Expense	2.521B	833.000M	300.000M	709.000M	679.000M	481.000M	166.000M	395.000M	469.000M
Net Profit Margin	20.1%	20.1%	15.0%	16.7%	16.9%	21.5%	10.1%	10.5%	14.9%
EBITDA	20.467B	5.673B	4.612B	5.227B	4.955B	5.035B	2.809B	4.102B	4.119B
EBITDA Margin	37.1%	37.1%	29.7%	34.4%	34.3%	37.1%	18.9%	30.2%	31.8%
Depreciation & Amortization	5.815B	1.366B	1.511B	1.549B	1.389B	1.284B	714.000M	1.817B	1.279B
EPS Basic	6.71	1.99	1.51	1.63	1.58	1.88	0.97	0.92	1.24
EPS Diluted	6.64	1.97	1.48	1.62	1.57	1.87	0.96	0.92	1.24
Shares Outstanding	1.549B	1.549B	1.550B	1.564B	1.550B	1.550B	1.550B	1.554B	1.554B
Diluted Shares Outstanding	1.561B	1.561B	1.562B	1.561B	1.559B	1.561B	1.562B	1.560B	1.560B

AZN Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Gross Profit	48.106B	43.866B	37.543B	31.960B	24.980B	21.318B	19.463B	17.154B
Revenue	58.739B	54.073B	45.811B	44.351B	37.417B	26.617B	24.384B	22.090B
Cost of Goods Sold	10.633B	10.207B	8.268B	12.391B	12.437B	5.299B	4.921B	4.936B
Gross Profit Margin	81.9%	81.1%	82.0%	72.1%	66.8%	80.1%	79.8%	77.7%
Total Operating Expenses	34.363B	33.863B	29.350B	28.203B	23.924B	16.156B	16.539B	13.767B
Research & Development	14.232B	13.583B	10.935B	9.762B	9.736B	5.991B	6.059B	5.932B
Selling, General & Administrative	20.512B	20.224B	18.222B	17.984B	15.590B	11.896B	11.985B	10.982B
Operating Income (EBIT)	13.743B	10.003B	8.193B	3.757B	1.056B	5.162B	2.924B	3.387B
Operating Margin	23.4%	18.5%	17.9%	8.5%	2.8%	19.4%	12.0%	15.3%
Income Before Tax (EBT)	12.402B	8.691B	6.899B	2.501B	-265.000M	3.916B	1.548B	1.993B
Interest Income	360.000M	345.000M	301.000M	81.000M	43.000M	83.000M	165.000M	138.000M
Interest Expense	1.694B	1.682B	1.589B	1.330B	1.276B	1.272B	1.402B	1.366B
Other Income/Expense	-1.341B	-1.312B	-1.294B	-1.256B	-1.321B	-1.246B	-1.376B	-1.394B
Net Income	10.255B	7.035B	5.955B	3.288B	112.000M	3.196B	1.335B	2.155B
Income Tax Expense	2.169B	1.650B	938.000M	-792.000M	-380.000M	772.000M	321.000M	-57.000M
Net Profit Margin	17.5%	13.0%	13.0%	7.4%	0.3%	12.0%	5.5%	9.8%
EBITDA	19.829B	15.438B	13.422B	9.085B	5.113B	8.084B	6.712B	7.112B
EBITDA Margin	33.8%	28.6%	29.3%	20.5%	13.7%	30.4%	27.5%	32.2%
Depreciation & Amortization	5.733B	5.065B	4.934B	5.254B	4.102B	2.896B	3.762B	3.753B
EPS Basic	6.60	2.27	3.81	2.12	0.08	2.44	1.03	1.70
EPS Diluted	6.54	2.25	3.81	2.11	0.08	2.44	1.03	1.70
Shares Outstanding	1.550B	1.550B	1.562B	1.548B	1.418B	1.312B	1.301B	1.267B
Diluted Shares Outstanding	1.562B	1.563B	1.562B	1.560B	1.427B	1.313B	1.301B	1.267B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About AstraZeneca PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Cambridge

94,300 employees

www.astrazeneca.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Pascal Claude Roland Soriot

View full financials